Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 5/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085695 | 0.89 | PTGS2 (0.60) | MAPTRXFP1TP53PTGS2MEN1 | |
| SCHEMBL6085793 | 0.89 | MAPT (0.57) | MAPTRXFP1TP53PTGS2 | |
| SCHEMBL6084433 | 0.84 | MAPT (0.63) | MAPTRXFP1TP53PTGS2MEN1 | |
| SCHEMBL6086106 | 0.84 | MAPT (0.55) | MAPTRXFP1TP53POLBMEN1 | |
| SCHEMBL6083913 | 0.84 | MAPT (0.48) | MAPTRXFP1TP53MEN1KMT2A | |
| SCHEMBL6084107 | 0.82 | UTRN (0.49) | MAPTRXFP1TP53POLBMEN1 | |
| SCHEMBL6085202 | 0.82 | MAPT (0.48) | MAPTRXFP1TP53POLBMEN1 | |
| SCHEMBL6085194 | 0.82 | MAPT (0.53) | MAPTRXFP1TP53POLBMEN1 | |
| SCHEMBL6085902 | 0.80 | SMN1; SMN2 (0.49) | MAPTTP53PTGS2MEN1KMT2A | |
| SCHEMBL6086084 | 0.80 | MAPT (0.49) | MAPTRXFP1TP53POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | claimed |
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | disclosed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | disclosed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | MAP3K15, MAP3K20, MAP3K3 | MAPT 801/4885RXFP1 4580/4885TP53 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.